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Sipa1 deﬁciency unleashes a host-immune
mechanism eradicating chronic myelogenous
leukemia-initiating cells
Yan Xu1,2, Satoshi Ikeda2, Kentaro Sumida2, Ryusuke Yamamoto1,2, Hiroki Tanaka2 & Nagahiro Minato1,2
Chronic myelogenous leukemia (CML) caused by hematopoietic stem cells expressing the
Bcr-Abl fusion gene may be controlled by Bcr-Abl tyrosine kinase inhibitors (TKIs). However,
CML-initiating cells are resistant to TKIs and may persist as minimal residual disease. We
demonstrate that mice deﬁcient in Sipa1, which encodes Rap1 GTPase-activating protein,
rarely develop CML upon transfer of primary hematopoietic progenitor cells (HPCs)
expressing Bcr-Abl, which cause lethal CML disease in wild-type mice. Resistance requires
both T cells and nonhematopoietic cells. Sipa1−/− mesenchymal stroma cells (MSCs) show
enhanced activation and directed migration to Bcr-Abl+ cells in tumor tissue and pre-
ferentially produce Cxcl9, which in turn recruits Sipa1−/− memory T cells that have markedly
augmented chemotactic activity. Thus, Sipa1 deﬁciency uncovers a host immune mechanism
potentially capable of eradicating Bcr-Abl+ HPCs via coordinated interplay between MSCs
and immune T cells, which may provide a clue for radical control of human CML.
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Cancer cells may induce dynamic reorganization of theirsurrounding tissue microenvironment including responsesby various host cells, such as mesenchymal stroma cells
(MSCs), vascular endothelial cells (ECs), and a variety of immune
and inﬂammatory cells1–3. Although such changes in tumor tis-
sue may signiﬁcantly inﬂuence tumor cell growth either positively
or negatively depending on the types and extents of tissue reac-
tions, in most cases the tumor cells evolve, expand, invade normal
tissues, and eventually metastasize. Acquired immunity has an
important role among the changes, and several cellular and
molecular signatures of immune contextures in tumor tissue are
often associated with a good prognosis for cancer patients4,5.
Nonetheless, the effects of host immunity, even against potently
immunogenic tumors, may be limited due to various hindrances,
including immune effectors having ineffective physical and/or
functional access to cancer cells in the tissue6. The discovery of
the PD-1-mediated immune checkpoint mechanism and recent
clinical success of checkpoint blockade therapy in cancer patients
have highlighted the importance of the functional accessibility of
immune T cells to cancer cells in the tissue microenvironment7–9.
Chronic myelogenous leukemia (CML) is caused by chromo-
somal translocations resulting in the generation of Bcr-Abl fusion
oncogene in a hematopoietic stem cells. Although the Bcr-Abl+
CML-initiating cells proliferate and differentiate under a hema-
topoietic hierarchy analogous to normal hematopoietic stem/
progenitor cells, they overwhelm normal hematopoiesis and lead
to a massive increase in the differentiated progenies10. The CML
cells induce remarkable alterations of the hematopoietic micro-
environment, which may favor the survival, proliferation, and
differentiation of CML-initiating cells over normal hematopoietic
counterparts11–13. The robust increase in CML cells during the
chronic phase may be controlled by Bcr-Abl tyrosine kinase
inhibitors (TKIs), but the CML-initiating cells per se are resistant
to TKIs14,15 and may persist as minimal residual disease16,17. It
has been reported that T cells speciﬁc for CML cells develop in
the patients, particularly under certain therapies, which may lead
to disease remission18,19. However, any contribution of endo-
genous acquired immunity in the host to the control of CML-
initiating cells usually appears to be very limited, if any, allowing
the disease progression20,21. Therefore, eradication of CML-
initiating cells remains a challenge for radical control of CML.
Sipa1 is a speciﬁc Rap1 GTPase-activating protein (GAP) that
negatively regulates Rap1 signaling22, which controls cell–cell and
cell–matrix interactions through the regulation of cell adhesion-
related molecules including integrins23–25. Although Sipa1-deﬁ-
cient mice remain healthy for a year or so after birth, they may
eventually develop diverse late-onset disorders in the immune
and hematopoietic systems, including overt systemic auto-
immunity and various hematological disorders with age26–28.
Such pleiotropic effects of Sipa1 deﬁciency may be accounted for
by the altered cellular interactions involved in the development of
various lymphohematopoietic cell lineages in the unique tissue
microenvironment29. It is reported that certain cancer cells may
overexpress Sipa1, which promotes their invasion and metastasis
via altered interaction with extracellular matrix (ECM) in the
tissue, thus functioning as a metastasis efﬁciency modiﬁer30–33.
As such, Sipa1 is a key endogenous regulator of cell adhesion and
migration for many cell types in tissues.
To explore the role of the host microenvironment in CML
development, we investigated the CML-inducing activity of pri-
mary Bcr-Abl+ hematopoietic progenitor cells (HPCs) from the
bone marrow (BM) of wild-type (Wt) mice in Sipa1−/− hosts. We
demonstrated that Sipa1−/−mice show a remarkable resistance to
CML development upon the transfer of Bcr-Abl+ HPCs, which
cause lethal CML disease in Wt mice. Current results uncovered a
novel mechanism potentially capable of eradicating Bcr-Abl+
HPCs and deterring CML disease development through immune
mechanisms via coordinated interplay between MSCs and
memory T cells in the tumor tissue.
Results
Sipa1-deﬁcient mice resist CML development by Bcr-Abl+
HPCs. To investigate the effects of the Sipa1-deﬁcient host
environment on the CML-inducing activity of the primary Bcr-
Abl+ HPCs, we ﬁrst transferred the primary lineage marker
negative (Lin−) BM cells from Wt B6 mice retrovirally trans-
duced with p210Bcr-Abl into Wt and Sipa1−/− B6 mice intrave-
nously at 1.5 × 104 cells/mouse according to the standard BM
transplantation (BMT) procedure34. Both Wt and Sipa1−/− mice
similarly died within 4 weeks after BMT with lethal or even
sublethal (5 Gy) γ-ray irradiation (Fig. 1a, left). Unexpectedly,
however, when Bcr-Abl+ HPCs were transferred to unirradiated
mice, all Sipa1−/− mice survived with no evidence of disease for
more than 100 days (Fig. 1a, right). All Wt mice died within
5 weeks, with only a slight delay compared to irradiated Wt mice
(Fig. 1a, right). The Wt mice developed a remarkable increase in
GFP+ leukocytes, which mostly consisted of myeloid cells in the
blood, and massive splenomegaly, but Sipa1−/− mice showed no
detectable GFP+ cells in the circulation and had no splenomegaly
(Fig. 1b). To examine the duration of the irradiation effect, we
transferred the Bcr-Abl+ HPCs at varying intervals after 5 Gy of
irradiation. All Wt recipients died within 4–5 weeks irrespective
of the intervals, as expected (Fig. 1c, left). In contrast, 100% and
20% of Sipa1−/− mice that were rested for more than 3 months
and for 2 months, respectively, before Bcr-Abl+ HPC transfer
survived with no evidence of disease, whereas all the mice with a
resting interval of <1 month died within 4 weeks (Fig. 1c, right).
The results indicated that the Sipa1−/− host environment con-
tributes potent resistance to the Bcr-Abl+ HPC-mediated CML
development, which is radiosensitive and needs at least 3 months
for full recovery after irradiation.
Bcr-Abl+ HPCs are properly engrafted in Sipa-1−/− BM. We
then investigated whether the transferred Bcr-Abl+ HPCs could
properly home to hematopoietic tissues and be engrafted in
unirradiated Sipa1−/− mice. FACS analysis indicated that a
detectable increase in GFP+ cells occurred in the BM of Wt
recipients on day 6, followed by an exponential increase thereafter
(Fig. 2a). GFP+ cells were then also increased in the peripheral
blood (PB) with a delay of ~3 days (Fig. 2a), suggesting that BM
was the primary site for the initial expansion and systemic spread
of Bcr-Abl+ cells. In Sipa1−/− recipients, GFP+ cells were also
increased in the BM until day 9 to an extent comparable to that in
Wt mice. However, the increase rate slowed on day 12, and the
GFP+ cells became essentially undetectable by day 15; the GFP+
cells in the PB were also transient and disappeared completely by
day 15 (Fig. 2a). Immunostaining analysis conﬁrmed the com-
parable presence of scattered GFP+ cells in the BM parenchyma
at as early as day 3, and on day 6 the clustered GFP+ cell foci
were observed to be similar in both Wt and Sipa1−/− recipients
(Fig. 2b, c). FACS analysis revealed essentially similar multi-
lineage differentiation proﬁles of Bcr-Abl+ HPCs in Wt and
Sipa1−/− recipients at day 9 (Supplementary Fig. 1). On day 12,
however, there were only minimal residual GFP+ cells in
Sipa1−/− BM, whereas remarkable GFP+ cell expansion was
evident throughout the BM of Wt mice (Fig. 2b, c). Many of the
residual GFP+ cells in Sipa1−/− BM on day 12 were noted to be
large cells, suggestive of differentiated megakaryocytes (Fig. 2c).
In agreement with these ﬁndings, the GFP+ Lin− c-Kit+ Sca-1+
(LKS) progenitor cells that increased until day 9 completely dis-
appeared by day 12 in Sipa1−/− mice, seemingly preceding the
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decline of total GFP+ cells (Fig. 2d). Further, although BMCs of
Sipa1−/− recipients on day 6 were capable of transferring the
CML disease to the secondary Wt B6 recipients as with Wt
recipients, BMCs of Sipa1−/− recipients on day 18 were no longer
able to do so (Fig. 2e). Thus, Bcr-Abl+ HPCs are properly
engrafted in the BM and initiated the proliferation and differ-
entiation, but they are eventually rejected completely in the
Sipa1−/− host.
CML resistance requires both hematopoietic and stromal cells.
Next, we addressed the cellular components of the host involved
in the rejection of Bcr-Abl+ HPCs in Sipa1−/− mice. Analysis
using EGFP; Sipa1 reporter mice revealed considerable expression
of Sipa1 in the both lymphohematopoietic and nonhematopoietic
cells in the BM (Fig. 3a). In the T-cell population, memory
CD44high cells exhibited greater Sipa1 expression than naive
CD44low cells of both CD4+ and CD8+ T-cell subsets (Fig. 3a), in
agreement with the transcriptional activation of Sipa1 via T-cell
receptor (TCR) stimulation27. Therefore, we challenged the BM
chimeric mice between Wt and Sipa1−/− mice with Wt Bcr-Abl+
HPCs at 4–6 months after BMT, allowing full recovery of the
resistance following γ-ray irradiation. As anticipated, <Wt BM
into Wt> mice all died within 4 weeks, whereas 100% of
<Sipa1−/− BM into Sipa1−/−> mice survived with no evidence of
disease for more than 100 days (Fig. 3b). All <Sipa1−/− BM into
Wt> mice also died similarly to <Wt BM into Wt> mice, indi-
cating that Sipa1−/− hematopoietic cells are ineffective in the Wt
host. On the other hand, 3 out of 12 <Wt BM into Sipa1−/−>
mice (25%) survived for long term, but the rest died similarly to
<Wt BM into Wt> mice (Fig. 3b). Although the results may imply
that Wt hematopoietic cells contribute to the resistance to a
certain extent in the Sipa1−/− host, the effect is much weaker
than that of Sipa1−/− hematopoietic cells. With the use of a Bcr-
Abl+ CML cell line BA-1, similar results were obtained (Sup-
plementary Fig. 2). The results strongly suggested that the robust
resistance of Sipa1−/− mice to CML development depends on
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Fig. 1 Bcr-Abl+ HPCs fail to develop CML in unirradiated Sipa1−/− mice. a Normal Lin− BM cells (HPCs) from Wt B6 mice were infected with retrovirus
containing p210Bcr-Abl and intravenously injected into Wt B6 and Sipa1−/− B6 mice at 1.5 × 104 cells per mouse with or without prior γ-ray irradiation.
Survival curves of the indicated numbers of mice per group are shown. Independent experiments were performed for two times with similar results. b On
day 20 after injection of Bcr-Abl+ HPCs, the proportions of GFP+ cells in the peripheral blood (PB) leukocytes and the weights of spleens were examined. A
bar indicates the mean spleen weight of control mice, and p values were determined with two-tailed unpaired Student’s t-test. Representative pictures of
spleens are also shown. Scale bar, 10 mm. cWt and Sipa1−/−mice were intravenously injected with Bcr-Abl+ HPCs at varying intervals after irradiation with
5 Gy γ-ray. Survival curves of ﬁve mice per group are shown. Independent experiments were done twice with similar results
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host. Sipa1−/− mice were no more resistant than Wt mice against
unrelated leukemia cell lines, such as the T-ALL cell line Wo1,
which also expresses GFP, and the T-cell leukemia cell line EL4
(Fig. 3c), and thus the resistance was apparently selective for Bcr-
Abl+ cells.
Sipa1−/− T cells are essential for the CML resistance. To
identify the hematopoietic cells involved in the resistance of
Sipa1−/− mice to Bcr-Abl+ HPCs, we performed genetic studies.
The resistance of Sipa1−/− mice was completely abolished by the
introduction of the Rag2−/− genetic background (Fig. 4a).
Sipa1−/− CD3ε−/− mice also developed lethal CML comparably
to Wt mice, whereas all Sipa1−/−μMT−/− mice remained disease
free for more than 100 days (Fig. 4b, c). Notably, both Sipa1+/+
Rag2−/− and Sipa1+/+ CD3ε−/− mice were by no means more
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Fig. 2 Bcr-Abl+ HPCs home to and initiate proliferation in BM but are eventually rejected in the Sipa1−/− host. a Bcr-Abl+ HPCs were intravenously injected
into unirradiated Wt and Sipa1−/− mice, and the proportions of GFP+ cells in the BM and PB were assessed with FACS on varying days after injection. The
means and standard errors (SEs) of eight mice are shown. The experiments were performed twice with similar results. b On day 3 after injection with Bcr-
Abl+ HPCs, BMs were immunostained with DAPI, anti-GFP antibody, and anti-CD105 antibody for endothelial cells. Arrows indicate the injected GFP+ cells
in the BM parenchyme. Scale bars, 20 μm. Similar results were conﬁrmed in three mice of each group. c On days 6 and 12, BMs were immunostained with
DAPI, anti-GFP, and anti-CD105 antibodies. The enlarged images of boxed regions are also shown. Scale bars, 1 mm and 100 μm (enlarged). Similar results
were obtained in three mice of each group. d The proportions of GFP+ Lin− cKit+ Sca-1+ (LKS) cells in the BM of Wt and Sipa1−/− mice were assessed
with FACS at varying days after injection of Bcr-Abl+ HPCs. The means and SEs of three mice per group are shown. *p < 0.01 (two-tailed unpaired Student’s
t-test). e BM cells from Wt and Sipa1−/− mice that received Bcr-Abl+ HPCs were harvested on day 6 and day 18, and intravenously injected into the
secondary unirradiated Wt B6 mice on a one-to-one basis. Survival curves of eight recipients per group are shown
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the Wt host. To investigate the role of T-cell subsets, we exam-
ined the effects of antibody-mediated cell depletion. Depletion of
either CD4+ or CD8+ T cells completely abolished the resistance
of Sipa1−/− mice, although natural killer (NK)-cell depletion had
no effect (Fig. 4d). These results indicated that acquired T-cell
immunity including both CD4+ and CD8+ T cells has a crucial
role in mediating the rejection of Bcr-Abl+ HPCs in Sipa1−/−
mice. In agreement with the ﬁndings, Sipa1−/− BM at day12 after
Bcr-Abl+ HPC transfer contained signiﬁcantly more T cells than
Wt BM with less GFP+ cells (p < 0.01, two-tailed unpaired Stu-
dent’s t-test), the increase being more prominent in CD8+ T cells
than CD4+ T cells (Fig. 4e). Also, the majority of increased T cells
were memory cell type (Fig. 4e), suggestive of systemic inﬂux.
Immunostaining analysis further conﬁrmed that the foci of GFP+
cells in the Sipa1−/− BM were associated with substantially more
T cells than those in Wt BM, and such T cells often formed a tight
adhesion to GFP+ cells (Supplementary Fig. 3).
CML resistance of Sipa1−/− host is not conﬁned to the BM. We
next addressed the nature of nonhematopoietic cells of Sipa1−/−
mice in the context of resistance to Bcr-Abl+ HPCs. To investi-
gate whether the resistance involves unique hematopoietic stroma
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Fig. 3 CML resistance of Sipa1−/− mice requires both hematopoietic and non-hematopoietic cells. a Expression of GFP in the BM cells of EGFP; Sipa1
reporter mice was analyzed with FACS at the gates of CD3+ CD44low CD62Lhigh CD4+ (naive CD4 T), CD3+ CD44high CD62Llow CD4+ (memory CD4
T), CD3+ CD44low CD62Lhigh CD8+ (naive CD8 T), CD3+ CD44high CD62Llow CD8+ (memory CD8 T), CD45+ B220+ (B-lineage), CD45+ CD11b+
(Myeloid), CD45− Ter119– CD31+ (Endothelial), and CD45– Ter119– CD31− PDGFRα+ (Mesenchymal). Shaded regions indicate staining with isotype-
matched control IgG. The intensities of GFP were conﬁrmed to correlate with the intracellular Sipa1 expression levels. b BM chimeras between Wt and
Sipa1−/− mice were generated for all four donor/recipient combinations as indicated. At the intervals of 4–6 months after BMT, Bcr-Abl+ HPCs of Wt mice
were intravenously injected into the chimeric mice at 1.5× 104 cells per mouse. Survival curves of indicated numbers of recipients per group are shown. c
Leukemia cell lines of B6 mice, BA-1 (Bcr-Abl+ CML), Wo-1 (T-ALL), and EL4 (T cell), were intravenously injected at 105 cells per mouse into Wt and
Sipa1−/− mice, and the survival rates were examined. Independent experiments were repeated for at least three times with similar results
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03307-8 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:914 | DOI: 10.1038/s41467-018-03307-8 |www.nature.com/naturecommunications 5
HPCs in Matrigel matrix to prevent systemic cell diffusion. The
“ectopic” transfer of Bcr-Abl+ HPCs into Wt mice also resulted in
the local expansion and tumor formation and eventually killed
the majority of recipients (Fig. 5a). Signiﬁcant GFP+ cells
appeared in the regional lymph nodes and circulation only at a
later stage. The Bcr-Abl+ HPCs in subcutaneous tissue showed
differentiation biased to B-lineage cells unlike in BM, where they
were mostly differentiated into myeloid cells (Supplementary
Fig. 4). This ﬁnding probably reﬂects the different hematopoietic
cytokines available in particular tissues. In contrast, the Bcr-Abl+
HPCs inoculated subcutaneously into Sipa1−/− mice initially
formed small nodules but were completely rejected after 3 weeks;
100% of the recipients remained tumor-free for more than
120 days, with no appearance of GFP+ cells in the circulation
either (Fig. 5a). Essentially similar results were obtained when
Sipa1−/− mice were subcutaneously challenged with BA-1 cells,
whereas EL4 leukemia cells formed progressive tumors compar-
ably in both Sipa1−/− and Wt mice (Fig. 5b). The resistance of
Sipa1−/− mice to subcutaneous Bcr-Abl+ HPCs was also
radiosensitive and dependent on T cells, including CD8+ T cells
(Supplementary Fig. 5, Fig. 5c). To further investigate the
immunological memory, we subcutaneously injected Sipa1−/−
mice with Matrigel matrix with or without Bcr-Abl+ HPCs on
one frank, followed by a challenge with Bcr-Abl+ HPCs on the
other frank at day 30, when the primary tumors were completely
rejected. Although control Sipa1−/−mice showed transient tumor
growth, those that rejected the tumors developed only negligible
tumors, suggesting an effective memory response (Fig. 5d). These
results suggested that nonhematopoietic cells required for the
rejection of Bcr-Abl+ HPCs in Sipa1−/− mice are not conﬁned to
the hematopoietic tissues.
Inﬁltration of MSCs and T cells inside CML of Sipa1−/− host.
We next performed histological analysis of the subcutaneous
tumors. The subcutaneously injected Bcr-Abl+ HPCs formed
tightly packed blastic tumor tissues in Wt mice with some small

















































































































Fig. 4 T cells of both CD4+ and CD8+ cell types are essential for CML resistance of Sipa1−/− mice. a–c Sipa1−/− mice were crossed with Rag2−/−,
CD3ε−/−, or μMT−/− mice to generate double KO mice, and Bcr-Abl+ HPCs of Wt B6 mice were intravenously injected in the unirradiated mice. Survival
curves of the indicated numbers of mice per group are shown. d Sipa1−/− mice were injected with anti-CD4, anti-CD8, anti-NK1.1 antibody, or control IgG
twice per week beginning from the day before the injection of Bcr-Abl+ HPCs. The antibody treatment was conﬁrmed to eliminate more than 95% of the
corresponding cell types in the spleen. Survival curves of the indicated numbers of mice per group are shown. e Wt and Sipa1−/− B6 mice were
intravenously injected with Bcr-Abl+ HPCs at 1.5 × 104 cells per mouse, and 12 days later the BM cells were harvested and multi-color analyzed with
indicated markers using FACS Canto. The means and SEs of cell numbers of indicated cell populations of ﬁve mice per group are shown. *p < 0.05;
**p < 0.01 (two-tailed unpaired Student’s t-test); m memory phenotype. The similar experiments were repeated two times with similar results
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contrast, tumor tissue in Sipa1−/− mice showed much dispersed
tumor cells that was heavily inﬁltrated with ﬁbroblastic and
mononuclear cells inside (Fig. 6a, right). Immunostaining analysis
revealed massive accumulation and invasion of vimentin-positive
MSCs and CD3+ T cells at largely coinciding areas in the tumor
tissues of Sipa1−/− mice, whereas these host cells were scarce in
the tumor tissues of Wt mice (Fig. 6b). At a higher magniﬁcation,
the vimentin-positive cells in Sipa1−/− mice showed spread
reticular forms and inﬁltrating CD3+ T cells were irregularly
shaped and often had tails, suggestive of activation (Fig. 6b).
FACS analysis conﬁrmed a remarkable increase in the propor-
tions of T cells relative to GFP+ tumor cells in the tissues of
Sipa1−/− mice and, to a lesser extent, B cells, macrophages, and
dendritic cells, with negligible γδT cells, NK cells, and granulo-
cytes (Fig. 6c). The actual numbers of both CD4+ and CD8+
T cells were also greater in the tumor tissues of Sipa1−/− mice,
the majority showed memory phenotype (Fig. 6d). The ratios of
CD8+ to CD4+ T cells tended to be greater in the tumors of
Sipa1−/− mice than in those of Wt mice (0.70 vs. 0.35), whereas
the proportions of Foxp3+ cells were comparable (about 10%).
The results suggested that MSCs play an important role in
rejecting Bcr-Abl+ CML cells along with T cells in the tumor
tissue of Sipa1−/− mice.
Activation of Sipa1−/− MSCs and T-cell chemokine secretion.
To assess the activation status of MSCs in tumor tissues, we
sorted the GFP− CD45− CD31− Ter119− cell populations mostly
representing mesenchymal cells from Bcr-Abl+ tumors of Wt and
Sipa1−/− mice for comparative DNA microarray. Gene set
enrichment analysis indicated a marked increase in several gene
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Fig. 5 Sipa1−/− mice reject the subcutaneous tumors by Bcr-Abl+ HPCs in a T-cell-dependent manner and develop immune memory. a Bcr-Abl+ HPCs in
Matrigel matrix were injected subcutaneously into Wt and Sipa1−/− mice at 1.5 × 104 cells per mouse, and the tumor volumes in the local sites were
measured. The means and SEs of tumor volumes and survival curves of ﬁve mice per group are shown. *p < 0.05 (two-tailed unpaired Student’s t-test). The
experiments were done at least three times with similar results. Representative pictures of tumor masses on day 20 are also indicated. Scale bars, 5 mm.
The white mass in Sipa1−/− mice represents residual Matrigel matrix. b BA-1 or EL4 leukemia cells were subcutaneously injected into Wt and Sipa1−/−
mice, and the tumor volumes were measured. The means and SEs of tumor volumes and survival curves of six mice per group are shown. *p < 0.05 (two-
tailed unpaired Student’s t-test). The experiments were performed four times. c Wt and Sipa1−/− mice were injected with anti-CD8 antibody or isotype-
matched IgG, followed by subcutaneous challenge with Bcr-Abl+ HPCs. The means and SEs of tumor volumes of four mice per group are shown. **p < 0.01
(two-tailed unpaired Student’s t-test). The experiments were done twice. d Sipa1−/− mice were subcutaneously injected with Bcr-Abl+ HPCs on one side of
frank. Thirty days later, when the tumors were completely rejected, these mice were rechallenged with Bcr-Abl+ HPCs on the other side of frank. Untreated
Wt and Sipa1−/− mice served as unimmunized controls. The means and SEs of tumor volumes of six mice per group are shown. *p < 0.05 (two-tailed
unpaired Student’s t-test)
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Fig. 6 Marked increase in memory T-cell inﬁltration inside Bcr-Abl+ tumors coinciding with increase vimentinhigh MSCs in Sipa1−/− mice. a Bcr-Abl+ HPCs
were subcutaneously injected in Matrigel matrix in Wt and Sipa1−/− mice, and the tumors on day 15 were ﬁxed and stained with hematoxylin and eosin.
Black arrows for Wt mice indicate mononuclear cell inﬁltration in the peripheral edges of the tumor mass. Scale bars, 100 and 20 μm (enlarged). The white
arrow and arrowhead indicate stromal reaction and dense mononuclear cell inﬁltration, respectively. Enlarged images of boxed regions are also shown. b
Serial sections of subcutaneous Bcr-Abl+ tumors in Wt and Sipa1−/− mice were immunostained with indicated antibodies. Enlarged images of boxed
regions are also shown. Scale bars, 200 and 50 μm (enlarged). c Subcutaneous Bcr-Abl+ tumors on day 15 in Wt and Sipa1−/− mice were dispersed into
single-cell suspensions in collagenase/DNase I solution and analyzed for the indicated cell markers with FACS. The means and SEs of the proportions of
ﬁve mice per group are shown. *p < 0.01 (two-tailed unpaired Student’s t-test). Experiments were done three times with similar results. d Subcutaneous
Bcr-Abl+ tumors on day 12 in Wt and Sipa1−/− mice were FACS analyzed, and the actual cell numbers of indicated cell types in tumor tissues were
calculated. The means and SEs of ﬁve mice per group are shown. m memory phenotype; *p < 0.01 (two-tailed unpaired Student’s t-test). Experiments were
done twice with similar results
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genes (Supplementary Fig. 6). Using quantitative polymerase
chain reaction (qPCR), we conﬁrmed that intratumor Sipa1−/−
MSCs at day 7 showed increased expression of mesenchymal
lineage genes (Vimentin, Sca-1, Icam1, Pdgfra, Pdgfrb, Snai1/2),
ECM- and ECM receptor-related genes (Col1a/3a, Intb1, Intb5,
Inta5, Inta11, IntaV), and ﬁbroblast growth factor (FGF) and
FGF receptor (FGFR) family genes (Fgfr1, Fgf1/2/7/10) (Fig. 7a).
Expression of α-Sma characteristic for reactive stroma was also
increased but only slightly. Using further puriﬁed PDGFRα+
MSC populations, essentially similar results were obtained.
Activation of Sipa1−/− MSCs was only transient and contracted
as the tumor cell burdens began to decrease at a later stage
(Supplementary Fig. 7a). In addition, intratumor Sipa1−/− MSCs
showed remarkably increased expression of Cxcl9, Cxcl10, and
Cxcl12 potentially capable of targeting activated T cells, with
minimal expression of other chemokines genes targeting
inﬂammatory myeloid cells (Fig. 7b). To examine actual che-
mokine secretion in the tumor tissue, we also performed protein
array analysis in the tumor tissue ﬂuids. The tumor tissue of
Sipa1−/− mice contained remarkably abundant Cxcl9 compared
to those of Wt mice (Fig. 7c). Notably, Sipa1−/− tumor tissue also
contained a high level of Ccl5, another potential T-cell chemo-
kine, although the Ccl5 expression was negligible in Sipa1−/−
MSCs (Fig. 7b, c). Intracellular FACS analysis revealed that Ccl5
was produced nearly exclusively by memory CD8+ T cells in the
tumor tissue of Sipa1−/− mice (Supplementary Fig. 7b). These
results suggest that Sipa1−/− MSCs are markedly activated and
secrete abundant T-cell chemokines in Bcr-Abl+ tumor tissue.
Sipa1−/− MSCs and T cells show enhanced migration activity.
Finally, we investigated the interaction mode of Sipa1−/− MSCs
with Bcr-Abl+ cells using primary mouse embryonic ﬁbroblasts
(MEFs) in vitro. Sipa1−/− MEFs showed markedly increased
phosphorylation of focal adhesion kinase (FAK), an essential
molecular component required for cell migration35, on collagen I
matrix compared to Wt MEFs with unchanged FAK protein level,







































































































































































































































































Fig. 7 Sipa1−/− MSCs in Bcr-Abl+ tumor tissue show mesenchymal gene activation with preferential production of T-cell chemokines. a, b MSCs (GFP−
CD45− Ter119− CD31−) were sorted from the subcutaneous tumors of Wt and Sipa1−/− mice on day 7 after subcutaneous injection of Bcr-Abl+ HPCs, and
the expression of indicated genes was assessed with quantitative PCR. Reanalysis of the sorted cell population indicated that the contamination of GFP+
cells was <0.5%. Three to four mice of each group were pooled for an experiment, and independent experiments were done twice with similar results. c
Cytokines and chemokines in the tissue ﬂuids of Bcr-Abl+ tumors of Wt and Sipa1−/− mice on day 15 after subcutaneous injection of Bcr-Abl+ HPCs were
assessed using mouse cytokine antibody array
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Fig. 8 Sipa1−/− MEFs show enhanced migration directed to Bcr-Abl+ CML cells and Sipa1−/− T cells augmented chemotaxis in response to chemokines. a
Wt and Sipa1−/− MEFs cultured on collagen I were lysed and immunoblotted with indicated antibodies. b Directed migration of Wt and Sipa1−/− MEFs to
BA-1 CML cells were assessed using the Boyden chamber assay in the presence of ﬁbronectin or collagen I. The means and SEs of quadruplicate culture are
shown, and p values were determined with two-tailed unpaired Student’s t-test. The experiments were repeated three times with similar results. Pictures of
crystal violet-stained migrated cells are also indicated. Scale bars, 50 μm. c In the Boyden chambers, anti-PDGFa antibody or isotype-matched control IgG
was added to the lower wells at 20 μg/mL with BA-1 cells. The means and SEs of quadruplicate culture are shown, and p values were determined with two-
tailed unpaired Student’s t-test. d Primary Lin− BM cells were transduced with p210Bcr-Abl or control vector. Three days later, GFP+ cells were sorted, and
Pdgfa expression was assessed with quantitative PCR (left). Expression of Pdgfa in BA-1, Wo-1, and EL4 cell lines was also examined (right). U.D.,
undetectable. e Chemotactic activity of sorted Wt and Sipa1−/− CD8+ T cells and CD4+ T cells that had been activated on the coated anti-CD3 antibody
for 24 h were assessed in response to Cxcl9 and Ccl5 (100 ng/mL) using the Boyden chamber assay in the presence or absence of ﬁbronectin. The means
and SEs of triplicate determination are shown. The experiments were repeated at least two times with similar results. *p < 0.01 (two-tailed unpaired
Student’s t-test)
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03307-8
10 NATURE COMMUNICATIONS |  (2018) 9:914 | DOI: 10.1038/s41467-018-03307-8 |www.nature.com/naturecommunications
Supplementary Fig. 8a). In the Boyden chamber assay, Sipa1−/−
MEFs showed signiﬁcantly enhanced directed migration to Bcr-
Abl+ BA-1 cells across the membrane compared to Wt MEFs (p
< 0.01, two-tailed unpaired Student’s t-test); the effect was more
prominent in the presence of ﬁbronectin than collagen I (Fig. 8b).
Such migrated Sipa1−/− MEFs showed markedly spread forms
compared to Wt MEFs (Fig. 8b). The enhancement of the ECM-
dependent directed migration, referred to as haptotaxis35, of
Sipa1−/− MEFs to BA-1 cells was signiﬁcantly inhibited in the
presence of anti-PDGFa or anti-PDGFRα antibody (p < 0.01, two-
tailed unpaired Student’s t-test) (Fig. 8c, Supplementary Fig. 8b).
We found that Bcr-Abl expression induced an increase in Pdgfa
expression in the primary BM HPCs; Bcr-Abl+ BA-1 cells con-
sistently exhibited signiﬁcant Pdgfa expression, whereas Wo-1
and EL4 cells did not (Fig. 8d). The results suggested the invol-
vement of leukemia-derived PDGF in the accumulation and
activation of Sipa1−/− MSCs inside Bcr-Abl+ tumor tissue. Given
that Sipa1−/− T cells are much more effective at rejecting Bcr-Abl
+ cells than Wt T cells in the Sipa1−/− environment, we also
examined the chemotactic activity in response to chemokines.
Activated Sipa1−/− T cells exhibited remarkably enhanced che-
motaxis compared to Wt T cells in response to Cxcl9 and, to a
lesser extent, Ccl5; the chemotaxis was also more prominent in
the presence of ﬁbronectin (Fig. 8e). In agreement with the
relative dominance of CD8+ T cells in the tumor tissue, Sipa1−/−
CD8+ T cells showed greater chemotactic activity than Sipa1−/−
CD4+ T cells (Fig. 8e). Altogether, these results suggest that Sipa1
−/− MSCs exhibit enhanced migration directed to Bcr-Abl+ cells
and secretion of Cxcl9, which causes efﬁcient recruitment of
Sipa1−/− memory T cells to the vicinity of the tumor cells
(Supplementary Fig. 9). Secretion of Ccl5 by such recruited CD8+
T cells may further amplify the T-cell recruitment inside the Bcr-
Abl+ tumor tissue.
Discussion
Sustained expression of Bcr-Abl in CML-initiating cells is essen-
tial for the maintenance and progression of CML disease36.
Although massive expansion and accumulation of CML cells
representing the differentiated progenies may be controlled by
TKIs, CML-initiating cells are much less sensitive to TKIs than
the majority of CML cells, partly because Bcr-Abl kinase activity
alone is not sufﬁcient to confer the leukemic stem cell activ-
ity15,17,37,38. Persisting CML-initiating cells as well as mutations
in Bcr-Abl kinase domain leading to drug resistance remain a
potential risk for disease recurrence39,40.
In the current study, we unexpectedly found that the primary
Bcr-Abl+ HPCs failed to develop CML disease in Sipa1−/− B6
mice, although they caused lethal CML with massive leukemic
expansion of Bcr-Abl+ cells in Wt B6 mice as expected. This
ﬁnding may be reminiscent of PD-1−/− mice that show strong
resistance to certain otherwise lethal tumors expressing PD-L17.
The resistance of Sipa1−/− mice was abrogated by prior γ-ray
irradiation and therefore overlooked in the standard procedures
for the mouse CML model using BMT34. The effect was not
attributable to the failure of the Sipa1−/− BM microenvironment
to support proper engraftment of transferred Bcr-Abl+ HPCs
because the Bcr-Abl+ HPCs did proliferate and differentiate until
about 10 days in Sipa1−/− BM comparably to Wt BM. Rather,
Sipa1−/− recipients actively rejected the Bcr-Abl+ cells later,
demonstrating a spontaneous cure with the complete elimination
of CML-initiating cell activity. Genetic as well as cell depletion
studies revealed that T cells of the Sipa1−/− host, including both
CD4+ and CD8+ cells, are essential for the rejection of Bcr-Abl+
HPCs, and the mice that once rejected Bcr-Abl+HPCs apparently
established the memory state. In agreement with the ﬁndings, a
much greater number of T cells were detected around Bcr-Abl+
cells in Sipa1−/− BM compared to those in Wt BM.
The resistance of Sipa1−/− mice was apparently selective for
Bcr-Abl+ CML in that Sipa1−/− mice were comparably suscep-
tible to other leukemia cells without Bcr-Abl expression relative to
Wt mice. Although Bcr-Abl+ CML expressed GFP in the current
model, Sipa1−/− mice were no more resistant than Wt mice to T-
ALL cells similarly expressing GFP, and thus it was unlikely that
GFP was involved in the immune rejection. The Bcr-Abl fusion
gene may create new antigenic epitopes, or neo-antigens, via a
codon slip, and Bcr-Abl-speciﬁc T cells are detected in the CML
patients18,41,42. It has also been reported that T cells speciﬁc for
proteinase 3 (P3), a self antigen that is abundantly and exclusively
expressed on normal myeloid cells, can emerge in CML patients
under allogeneic BMT or interferon-α therapy but rarely in
untreated patients; notably, the generation of these cells corre-
lated with disease remission19. Sipa1−/− mice are prone to sys-
temic autoimmunity28, and an intriguing possibility is that the
Sipa1−/− host favors the development of such T cells speciﬁc for
self antigens expressed on robustly expanding CML cells. In
either case, Bcr-Abl+ CML cells can be potentially immunogenic
for T cells, and crucial tumor-rejection antigens involved in a
current model remain to be veriﬁed.
Current results, however, also revealed that Sipa1−/− T cells
are ineffective for rejecting Bcr-Abl+ HPCs in the Wt host
environment. Thus, analysis using BM chimeric mice indicated
that neither <Wt BM into Sipa1−/−>mice nor <Sipa1−/−BM into
Wt>mice showed strong CML resistance comparable to that of
<Sipa1−/− BM into Sipa1−/−>mice, suggesting that the combi-
nation of Sipa1−/− T cells and Sipa1−/− nonhematopoietic cells is
essential for the complete rejection. Sipa1−/−, but not Wt, mice
also rejected subcutaneous Bcr-Abl+ tumors completely, sug-
gesting that the required Sipa1−/− nonhematopoietic cells do not
need to be specialized hematopoietic stroma cells. Histological
analysis revealed a remarkable accumulation of vimentin-positive
MSCs in concordance with abundant penetration of T cells inside
the Bcr-Abl+ tumor tissue of the Sipa1−/− host. In the Wt host,
MSCs were scarcely detected in the tightly packed tumor tissue,
and T cells remained at the peripheral margins of the tissue, if
any. The results are consistent with the notion that inﬁltration of
T cells in the center of tumor tissue is crucial for tumor regres-
sion5, and they suggest that the accumulation and/or persistence
of Sipa1−/− MSCs around the Bcr-Abl+ tumor cells plays an
important role in the intratumor T cell recruitment. Notably, γ-
ray radiation profoundly damages not only T cells but also
MSCs43.
Intratumor Sipa1−/− MSCs showed signiﬁcant activation of
selective gene sets, including mesenchymal lineage genes, ECM
and integrin genes, and FGF-related genes, compared to those in
Wt mice. Because Sipa1 in the cytosol binds the nuclear chro-
matin modifying factor Brd4, which regulates the expression of a
panel of ECM and the related receptor genes44,45, the increase in
nuclear Brd4 in Sipa1−/− MSCs may underlie the effects31,32.
Enhanced Rap1 activation linked to protein tyrosine kinase
(PTK) receptors in Sipa1 deﬁciency may also contribute to MSC
activation via augmented MAPK signaling22,24. We found that
Bcr-Abl expression in the primary HPCs induces Pdgfa expres-
sion. MSCs constitutively express PDGFR, and PDGF is a prin-
cipal factor inducing the activation of MSCs, including directed
cell migration via chemotactic ECM cues, called haptotaxis35,46.
Sipa1−/− MEFs showed markedly enhanced basal FAK activation
and haptotaxis directed to Bcr-Abl+ BA-1 cells in an ECM-
dependent manner compared to Wt MEFs, and the effect was
inhibited in the presence of either anti-PDGF or anti-PDGFR
antibody. Therefore, we suggest that tumor-derived PDGF may
be involved, at least partly, in the accumulation and activation of
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Sipa1−/−MSCs in the center of tumor tissue. The role of resident
MSCs in tumor tissue is controversial. Certain human cancers
such as breast cancers are often associated with persistent
“reactive stroma” consisting of ﬁbroblasts showing characteristic
phenotypic transition, including strong α-smooth muscle actin
(SMA) expression47. Such cancer-associated ﬁbroblasts that
develop under the inﬂuence of transforming growth factor
(TGF)-β may show tumor-promoting and/or immunosuppressive
activity, often correlating with poor patient prognosis3,48,49.
However, resident ﬁbroblasts in tumor tissue have been reported
to potentially be able to inhibit tumor progression50; for instance,
blocking TGF-β signaling in MSCs reveals the tumor-suppressive
activity51.
Importantly, Sipa1−/−MSCs, but rarely Wt MSCs, in Bcr-Abl+
tumor tissue preferentially and strongly expressed chemokine
genes such as Cxcl9 (Mig) targeting memory T cells with minimal
proinﬂammatory chemokines targeting myeloid cells. A recent
study has suggested that tissue MSCs may develop into distinct
functional subsets depending on the nature of microenviron-
mental stresses52. It remains to be seen whether the Sipa1−/−
MSCs preferentially producing Ccl9 represent a unique functional
subset or reﬂect the speciﬁc mode of MSC activation in the
absence of Sipa1. Furthermore, activated Sipa1−/− T cells, in
particular CD8+ cells, exhibited markedly enhanced chemotactic
activity in response to Cxcl9, most likely due to the increased
Rap1-mediated inside-out activation of migratory integrins23. We
found that Sipa1−/− memory CD8+ T cells in tumor tissue fur-
ther produce Ccl5 (Rantes), which shows potent TCR costimu-
latory activity for CD4+ T cells in addition to T-cell chemotactic
activity53. The results revealed a potentially important role of
MSCs in recruiting memory T cells in the center of tumor tissue
to ensure their direct encounter with tumor cells for the immune
effects. The mechanism is remarkably potentiated in the Sipa1−/−
host, leading to the complete immunological eradication of CML;
however, it remains rather latent in the Wt host. Most recently,
cooperation between T cells and nonhematopoietic stroma cells
leading to the rejection of a head and neck cancer cell line was
reported in mice with combined deﬁciency of Toll-like receptors 3,
7, and 954.
Large-scale cancer patient analyses have indicated that speciﬁc
patterns of immune activation within tumor tissues are associated
with a better prognosis for cancer patients. These patterns include
an abundance of memory T cells as well as molecular signatures
related to T-cell chemotaxis, cytotoxicity, and cell adhesion5.
Notably, the location of T cells in the center and invasive margin
of tumor tissue is signiﬁcantly correlated with better prog-
nosis55,56. Therefore, in clinical settings, recruitment of memory
T cells inside the tumor tissue ensuring the functional access of
immune T cells to tumor cells may be important for suppressing
tumor progression. Our current study suggests that the coordi-
nated interplay between MSCs and immune T cells inside tumor
tissue has a strong potential for leading to a cure for CML disease.
Although it remains to be proven whether properly accessed
immune T cells can directly affect TKI-resistant CML-initiating
cells and Bcr-Abl mutant cells, current results may provide a
novel clue for radically controlling human CML.
Methods
Mice. C57BL/6 (B6) mice were purchased from Charles River Laboratories Inc.
(Kanagawa, Japan) and SLC Inc. (Shizuoka, Japan). Rag2−/− mice were obtained
from Central Institute of Experimental Animals (Kanagawa, Japan). CD3ε−/− and
μMT−/− mice were provided by Dr. S. Fagarasan (RIKEN Center for Integrative
Medical Science, Kanagawa, Japan) and Dr. M. Reth (Albert Ludwigs Universität
Freiburg, Freiburg, Germany), respectively. All these mutant mice had a B6 genetic
background. Sipa1−/− mice have been reported previously26 and crossed with B6
mice for more than 15 generations. Enhanced GFP (EGFP)-Sipa1 reporter (EGFP;
Sipa1 KI) mice were generated as a custom order by Unitech (Kashiwa, Chiba,
Japan). In brief, the Sipa1 chromosomal gene was isolated from bacterial artiﬁcial
chromosome clones of C57BL/6 mice, and its exon 4 was replaced by a coding
sequence for EGFP and loxp-neo-loxp genes. The targeting vector containing the
diphtheria toxin A fragment upstream exon 9 was transfected into embryonic stem
(ES) cells (clone: Bruce 4) derived from C57BL/6 mice. The ES clones carrying the
targeted allele were introduced into host embryos, and the chimeric mice were
crossed with the CAG-Cre transgenic mice. In all experiments, male and female
mice of 6–8-week old were used, and the numbers of mice used in experiments
were indicated in ﬁgure legends. All mice were maintained in speciﬁc pathogen-
free conditions at the Center for Experimental Animals of Kyoto University, and all
animal experiments were performed strictly according to the institutional guide-
lines by Kyoto University Animal Ethics Committee.
Cells and cultures. The BA-1 cell line was established from the bone marrow cells
(BMCs) of young Sipa1−/− mice by infection with pMSCV-IRES-GFP retroviral
plasmid (MIG) containing human p210 Bcr-Abl. The Wo-1 cell line was established
from thymic T-cell acute lymphoblastic leukemia (T-ALL) developed by the BMT
of HPCs transduced with MIG containing C3G-F57, and the T-cell leukemia cell
line, EL4, was purchased from American Type Culture Collection. The cells were
cultured with complete BXH-2 medium supplemented with 10% fetal calf serum
(FCS)26. The leukemic cell lines were authenticated by the gene expression (C3G-F)
and FACS analysis of markers (CD3, CD4). Mouse embryonic ﬁbroblasts (MEFs)
were obtained from the embryos of Wt and Sipa1−/− mice on day 15.5 of gestation
and maintained with Dulbecco’s modiﬁed Eagle medium (DMEM) containing 10%
FCS, unless otherwise speciﬁed. The MEFs were checked for the expression of
Sipa1 with immunoblotting. All cells were tested for mycoplasma contamination.
Retrovirus infection and cell transfer. Bone marrow cells (BMCs) from 4- to 6-
week-old B6 mice pretreated with 150 mg/kg 5-ﬂuorouracil (5-FU; Kyowa Hakko
Kogyo, Tokyo, Japan) were depleted of lineage marker-positive (Lin+) cells using a
cocktail of antibodies (anti-CD3, anti-CD4, anti-CD8, anti-B220, anti-Gr-1, anti-
Mac-1, and anti-Ter119 antibodies; BD Bioscience, San Jose, CA, USA) and anti-
rat IgG-coated magnetic beads (Supplementary Table 1) (Dynabeads M-450;
Dynal, Oslo, Norway). The resulting Lin− BMCs enriched for HPCs were infected
with MIG/p210Bcr-Abl retrovirus as previously reported58. Brieﬂy, the cells were
infected with retroviral supernatants by spinoculation and cultured in complete
BXH-2 medium containing 10 ng/mL IL-6, 10 ng/mL IL-11, 10 ng/mL Flt-3 ligand,
and 50 ng/mL stem cell factor (Genzyme, Minneapolis, MN) for 48 h. Infection
efﬁciency was 30–35%. The infected cells were injected intravenously or sub-
cutaneously into mice at 1.5 × 104 cells per mouse. For subcutaneous injection, the
GFP+ HPCs were placed in Matrigel matrix (Corning, Tewksbury, MA, USA) to
prevent rapid cell diffusion.
BM chimeras. BMCs from Wt or Sipa1−/− mice were injected intravenously into
Wt or Sipa1−/− mice irradiated with 13-Gy γ-ray (6.5 Gy twice with a 4-h interval)
at 2 × 107 cells per mouse. Chimeric rates in the procedures were more than 95%.
Chimeric mice were rested for 4–6 months before the challenge with Bcr-Abl+
HPCs.
Flow cytometry. Multicolor ﬂow cytometric analysis was performed with FACS
Canto (BD Bioscience, San Jose, CA, USA), and the data were analyzed with FlowJo
(Tree Star). Cells were Fc-blocked (CD16/CD32) and stained with antibodies
(Supplementary Table 1). Propidium iodide or Ghost dyeTM Violet 450 (Tonbo
Biosciences) was used to exclude dead cells. Intracellular staining for Ccl5 was
performed with cells ﬁxed and made permeable with IC Fixation Buffer and Per-
meabilization Buffer (eBioscience) according to the manufacturer’s instructions.
Immunostaining. Femoral bones or subcutaneous tumor tissues were ﬁxed in 2%
paraformaldehyde for 2 h at room temperature and left in 30% sucrose at 4 °C
overnight before embedding in optimum cutting temperature compound (Sakura,
Torrance, CA). Serial frozen sections were blocked with 5% donkey serum in
phosphate-buffered saline (PBS) overnight followed by immunostaining with
antibodies (Supplementary Table 1) as before59. Stained tissues were mounted with
Mowiol 4–88 (Calbiochem), and images were acquired with the use of ﬂuorescence
microscopy (Axiovert 200M) equipped with an AxioCam MRm Fluar 2.5×/0.12 or
5×/0.25 numerical aperture objective lens (Carl Zeiss) and analyzed with Axio-
Vision version 4.6 (Carl Zeiss). Digital images were processed using Adobe Pho-
toshop CS2 (Adobe). For immunostaining of MEFs, cells were grown on coverslips
(Matsunami Glass Ltd., Japan), ﬁxed with 4% paraformaldehyde for 10 min at
room temperature, permeabilized with 0.1% Triton X-100 for 5 min, blocked with
5% BSA/PBS for 1 h, and incubated with primary antibodies for 1 h at room
temperature followed by secondary antibodies and DAPI for 30 min. The anti-
bodies used were anti-phospho-FAK (ab81298; Abcam, Cambridge, UK, at 1:1000
dilution), Alexa Fluor 568 Phalloidin (Invitrogen), and Alexa Fluor 488. Images
were obtained using the BZ-X700-All-in-One ﬂuorescence microscope (Keyence).
Antibody-mediated cell depletion. To speciﬁcally deplete NK cells in vivo, anti-
NK1.1 antibody (PK136) was injected intraperitoneally at 200 μg per mouse twice
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03307-8
12 NATURE COMMUNICATIONS |  (2018) 9:914 | DOI: 10.1038/s41467-018-03307-8 |www.nature.com/naturecommunications
per week before and once per week after Bcr-Abl+ HPC injection. For CD4+ and
CD8+ T-cell depletion, anti-CD4 (GK1.5) and anti-CD8 (2.34) antibodies were
injected at 150 μg per mouse, respectively, 2 days before and twice per week after
Bcr-Abl+ HPC injection. Control groups were treated with corresponding isotype-
matched control IgG. The procedures were conﬁrmed to have depleted more than
95% of the corresponding cell populations.
Tumor measurement and isolation of tumor-inﬁltrating cells. The sizes of
subcutaneous tumors were measured in two dimensions, and the volumes were
assessed by the following formula: tumor volume= l/2 ×w2. Tumor tissues (5 mg)
were cut into small pieces in 1 mg/mL Collagenases IV and DNase I in 2%
FCS RPMI-1640 medium. After 60 min of incubation with gentle shaking at 37 °C,
the cells were strained through a 40-μm nylon mesh to produce a single-cell
suspension. To isolate mesenchymal stroma cells (MSCs), the cell suspensions were
stained with anti-GFP and anti-CD45-BV510 (30-F11; BD Bioscience), anti-
TER119-BV510 (TER119; BD Bioscience), anti-CD31-APC (390; BioLegend), and
anti-PDGFRα (APA5; eBioscience) antibodies at 1 μg/mL. The GFP− CD45−
Ter119− CD31− PDGFRα+ cell population was sorted with FACS Aria III (BD
Bioscience). In some experiments, anti-PDGFRα was omitted to ensure enough cell
numbers. Contamination of GFP+ cells and CD31+ ECs in the MSC population
was less than 0.5% and 0.1%, respectively.
DNA microarray and qPCR analysis. RNA was extracted from the sorted GFP−
CD45− Ter119− CD31− cell populations and subjected to DNA microarray ana-
lysis (TaKaRa Bio Inc., Siga, Japan). Gene expression proﬁling was performed using
total RNA and DNA microarray (SurePrint G3 Mouse Gene Expression v2 8 × 60 K
Microarray Kit, Agilent) according to manufacturer’s protocol. Probes with con-
ﬁdent expression signals were selected using ﬂags produced by Feature Extraction
software: IsSaturated= 0, IsFeatNonUnifOL= 0, IsBGNonUnifOL= 0, IsPo-
sAndSignif= 1 and IsWellAboveBG= 1. All selected probes corresponding to
~19,000 genes were subjected to Gene Set Enrichment Analysis using expression
log ratio log2 (KO/WT) as rank metrics. The analysis was done with following
settings: preranked analysis mode of GSEA software (version 2.2.4, Broad Institute)
and gene sets from category Hallmark and C2, which were prepared in MSigDB
(Broad Institute). Quantitative PCR was performed with SYBR Green I Master mix
(Roche) on a LightCycler 480 (Roche). Transcripts of b-actin were used as an
internal control. Primer sequences for genes are listed in the Supplementary
Table 2.
Cytokine array analysis. Cytokine levels in tumor tissue supernatants were
measured using Mouse Cytokine Antibody Array, Panel A (R&D Systems),
according to the manufacturer’s instructions. Samples were analyzed as singlets
using a LAS-4000 mini instrument with Image Reader Las-4000 mini and Multi
Gage V3.2 software (Fujiﬁlm).
Cell migration assay. The haptotaxis assay was performed using the CytoSelectTM
24-Well Cell Haptotaxis Assay Kit (8 µm, ﬁbronectin-coated or collagen-coated,
Cell Biolabs, Inc.) with 8.0-µm pore membrane inserts coated with ﬁbronectin or
collagen I, according to the manufacturer’s procedures. Brieﬂy, MEFs (1 × 104 cells)
prestarved of serum for 1 h were applied to the upper wells in the presence or
absence of 2 × 106 BA-1 cells in the lower wells in DMEM containing 0.1% FCS,
followed by incubation at 37 °C for 4 h. When indicated, 20 μg/mL anti-PDGFa
(Upstate), anti-PDGFRα (R&D Systems), or isotype-matched control IgG was
added to the lower wells. The outer parts of the inset membranes were stained with
crystal violet, and OD 560 nm was measured with ARBOTM X 2030 Multilabel
Reader (PerkinElmer). The chemotaxis assay was performed using 24-well plates
and 6.5-mm Transwell with 5.0-µm pore polycarbonate membrane inserts
(Corning, NY, USA). Inserts were coated with 10ug/mL ﬁbronectin (Invitrogen)
for 1 h and dried. CD4+ and CD8+ T cells were isolated with autoMACS Pro
Separator (Miltenyi Biotec, Bergisch Gladbach, Germany) and added to the upper
chamber (5 × 105 cells) in 1% BSA RPMI-1640. The lower chambers were ﬁlled
with 1% BSA RPMI-1640 containing Cxcl9 or Ccl5 (PeproTech, Rocky Hill, NJ,
USA) at 100 ng/mL. After 3 h of incubation in 5% CO2 at 37 °C, the cells that
migrated into the lower chambers were counted by FACS Canto (BD Bioscience).
Immunoblotting. MEFs were lysed with lysis buffer (150 mM NaCl, 25 mM Tris-
HCl, 1%NP-40, 1% Na deoxycholate, 0.1% SDS) and blotted with anti-Sipa126,
anti-FAK (ab40794;Abcam, Cambridge, UK), or anti-phospho-FAK (Y397;Abcam,
Cambridge, UK) antibody at 1:1000 dilution. Uncropped original scan images are
shown in Supplementary Fig. 10.
Statistical analyses. Statistical analyses were performed using the unpaired two-
tailed Student’s t-test and one-way ANOVA with Bonferroni post hoc test.
Spearman’s rank test was used to determine correlations; p < 0.05 indicated a
signiﬁcant difference. In animal experiments, it was not feasible to make an
assumption of sample sizes based on the log-rank statistic, because we have never
observed the development of lethal CML in Sipa1−/− mice for observation period
of 100 days (i.e., zero event numbers). Age-matched mice kept in the same animal
room were used with no particular randomization, and no mice were excluded
from the analysis. The investigators were not blinded for group allocations.
Data availability. The DNA Microarray data were deposited in Gene Expression
Omnibus (GEO) repository, NCBI (GSE108002, https://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE108002). The authors declare that all the other data
supporting the ﬁndings of this study are available within the article and its Sup-
plementary Information ﬁles and from the corresponding author upon reasonable
request.
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